384 related articles for article (PubMed ID: 30348170)
21. Qualitative evaluation of a peer-based needle syringe programme in Vietnam.
Ngo AD; Schmich L; Higgs P; Fischer A
Int J Drug Policy; 2009 Mar; 20(2):179-82. PubMed ID: 18242971
[TBL] [Abstract][Full Text] [Related]
22. An external evaluation of a peer-run "unsanctioned" syringe exchange program.
Wood E; Kerr T; Spittal PM; Small W; Tyndall MW; O'Shaughnessy MV; Schechter MT
J Urban Health; 2003 Sep; 80(3):455-64. PubMed ID: 12930883
[TBL] [Abstract][Full Text] [Related]
23. Unmet needs and harm reduction preferences of syringe services program participants: differences by co-use of illicit opioids and methamphetamine.
Sun R; Sauda TH; Hoopsick RA
Harm Reduct J; 2024 Jun; 21(1):119. PubMed ID: 38890736
[TBL] [Abstract][Full Text] [Related]
24. Harm reduction product distribution in British Columbia.
Harvard SS; Hill WD; Buxton JA
Can J Public Health; 2008; 99(6):446-50. PubMed ID: 19149383
[TBL] [Abstract][Full Text] [Related]
25. Harm reduction interventions, behaviours and associated health outcomes in France, 1996-2003.
Emmanuelli J; Desenclos JC
Addiction; 2005 Nov; 100(11):1690-700. PubMed ID: 16277629
[TBL] [Abstract][Full Text] [Related]
26. [Community collection of syringes by parenteral drug users complementary to syringe exchange programs].
Bechich S; Martínez M; Llorella G; Rodés A; De Andrés M; Delás J
Gac Sanit; 2001; 15(4):353-5. PubMed ID: 11578566
[TBL] [Abstract][Full Text] [Related]
27. People who use drugs engagement in substance use disorder services and harm reduction: evaluation, challenges and future direction of a community-based intervention.
Gleason-Comstock J; Calhoun CB; Locke BJ; Boorle NVLD; Cobty K; McKenney T; Uddin KO; Bauer SJ; Xu J
Subst Abuse Treat Prev Policy; 2024 Apr; 19(1):24. PubMed ID: 38689339
[TBL] [Abstract][Full Text] [Related]
28. The Harm Reduction Coalition.
Clear A; Springer E; Lanier C
Newsline People AIDS Coalit N Y; 1998 Jun; ():27-34. PubMed ID: 11367469
[TBL] [Abstract][Full Text] [Related]
29. The effect of on-site and outreach-based needle and syringe programs in people who inject drugs in Kermanshah, Iran.
Nazari SS; Noroozi M; Soori H; Noroozi A; Mehrabi Y; Hajebi A; Sharifi H; Higgs P; Mirzazadeh A
Int J Drug Policy; 2016 Jan; 27():127-31. PubMed ID: 26764125
[TBL] [Abstract][Full Text] [Related]
30. Syringe exchange in community pharmacies--The Portuguese experience.
Torre C; Lucas R; Barros H
Int J Drug Policy; 2010 Nov; 21(6):514-7. PubMed ID: 20956074
[TBL] [Abstract][Full Text] [Related]
31. Shifting the paradigm: physician-authorized, student-led efforts to provide harm reduction services amidst legislative opposition.
McMullen TP; Naeim M; Newark C; Oliphant H; Suchard J; Banimahd F
Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):27. PubMed ID: 33761954
[TBL] [Abstract][Full Text] [Related]
32. Doing harm reduction better: syringe exchange in the United States.
Des Jarlais DC; McKnight C; Goldblatt C; Purchase D
Addiction; 2009 Sep; 104(9):1441-6. PubMed ID: 19215605
[TBL] [Abstract][Full Text] [Related]
33. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020.
Behrends CN; Lu X; Corry GJ; LaKosky P; Prohaska SM; Glick SN; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC
Drug Alcohol Depend; 2022 Mar; 232():109323. PubMed ID: 35124386
[TBL] [Abstract][Full Text] [Related]
34. Long-term survey of a syringe-dispensing machine needle exchange program: answering public concerns.
Duplessy C; Reynaud EG
Harm Reduct J; 2014 May; 11():16. PubMed ID: 24885902
[TBL] [Abstract][Full Text] [Related]
35. Harm reduction, hepatitis C and opioid pharmacotherapy: an opportunity for integrated hepatitis C virus-specific harm reduction.
Hallinan R; Byrne A; Dore GJ
Drug Alcohol Rev; 2007 Jul; 26(4):437-43. PubMed ID: 17564882
[TBL] [Abstract][Full Text] [Related]
36. Harm reduction drug policy in Israel: what has been accomplished and what still needs to be done?
Bonny-Noach H
Isr J Health Policy Res; 2019 Oct; 8(1):75. PubMed ID: 31619286
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of needle and syringe programs in Tajikistan distributing low dead space needles.
Zule WA; Latypov A; Otiashvili D; Bangel S; Bobashev GV
Harm Reduct J; 2018 Aug; 15(1):44. PubMed ID: 30170604
[TBL] [Abstract][Full Text] [Related]
38. Intersecting substance use treatment and harm reduction services: exploring the characteristics and service needs of a community-based sample of people who use drugs.
Krawczyk N; Allen ST; Schneider KE; Solomon K; Shah H; Morris M; Harris SJ; Sherman SG; Saloner B
Harm Reduct J; 2022 Aug; 19(1):95. PubMed ID: 36002850
[TBL] [Abstract][Full Text] [Related]
39. Challenges and value of peer outreach workers in needle and syringe exchange programs: Evidence from an HIV prevention program in Yunnan province, China.
Haw NJ; Yang J; Li H; Duo L; Wang Z; Bouey JZH
J Ethn Subst Abuse; 2020; 19(3):403-416. PubMed ID: 30431407
[TBL] [Abstract][Full Text] [Related]
40. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia.
Salmon AM; van Beek I; Amin J; Kaldor J; Maher L
Addiction; 2010 Apr; 105(4):676-83. PubMed ID: 20148794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
